CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the...
Read More Details
Finally We wish PressBee provided you with enough information of ( Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal )
Also on site :
- 'Explosive-laden vehicle hit convoy': 16 Pakistan troops killed in suicide attack
- USPS slammed as ‘failed system’ after 1,000s of letters & packages found abandoned in mail centers following huge delays
- What is Thimerosal, vaccine preservative called ‘toxic’ by US health chief?